| Revenue growth | 21% growth in FY26; high-teen growth guided for FY27. |
|---|---|
| Margins | 78% gross margin; FY27 EBITDA margin guided at 27%. |
| Order book | Improved order flow in Africa Institutional segment. |
| Demand visibility | Strong across branded generics; US momentum continues. |
| Management confidence | High; confidence in sustaining momentum and Asia recovery. |
Growth
FY26 revenue grew 21%, EBITDA 11%, and PAT 15%. US Generics surged 49% for the full year.
Outlook
FY27 guidance: high-teen revenue growth, 27% EBITDA margin, and ₹400cr capex plan.
Risks
Geopolitical issues in Middle East caused supply chain disruptions in Asia; rising freight and RM-PM costs.
Earnings Call filed with BSE, NSE: AJANTPHARM. Summary written with AI assistance from the document.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,569.80
- Market cap
- ₹44,608 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 39.3×Sector 47.3×
- Promoter holding
- 63.48%-2.77% QoQ
- FII holding
- 7.68%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Share Pledge
Aayush Agrawal (Trustee of Aayush Agrawal Trust) has released a pledge on 1,736,353 equity shares of Ajanta Pharma Limited. This follows loan repayment.
Ajanta Pharma Share Pledge
Promoter Aayush Agrawal Trust released pledge on 9.76 lakh shares and created a new pledge on 9.20 lakh shares of Ajanta Pharma Limited.
Ajanta Pharma Share Pledge
Promoter Ravi Agrawal, as trustee of Ravi Agrawal Trust, released a pledge on 54,796 equity shares of Ajanta Pharma Limited due to excess pledge.
Ajanta Pharma Earnings Call Transcript: Key Takeaways
Ajanta Pharma reports strong Q1 FY27 results, but management remains cautious about sustainability, guiding for normalization in the US and acknowledging geopolitical headwinds in Asia.
- Call
- Guides 18% growth
Ajanta Pharma Employee Stock Options
Ajanta Pharma Limited has allotted 23,400 equity shares following the exercise of employee stock options. Consequently, the company's paid-up share capital increased to Rs. 24.99 Crore.
Ajanta Pharma Dividend
Ajanta Pharma Limited has fixed August 5, 2026, as the record date. This date determines shareholder eligibility for the payment of the first interim dividend.